Citizens Financial Group Inc. RI Decreases Stake in Eli Lilly and Company (NYSE:LLY)

Citizens Financial Group Inc. RI lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.7% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 50,575 shares of the company's stock after selling 2,512 shares during the period. Eli Lilly and Company accounts for about 0.9% of Citizens Financial Group Inc. RI's holdings, making the stock its 22nd largest holding. Citizens Financial Group Inc. RI's holdings in Eli Lilly and Company were worth $44,806,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the business. Peterson Financial Group Inc. bought a new stake in shares of Eli Lilly and Company in the third quarter valued at about $27,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $30,000. Lynx Investment Advisory acquired a new position in Eli Lilly and Company in the second quarter valued at about $32,000. LGT Financial Advisors LLC acquired a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $36,000. Finally, Morton Brown Family Wealth LLC increased its holdings in Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company's stock valued at $41,000 after buying an additional 15 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the business's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares of the company's stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Down 1.2 %

Shares of LLY traded down $8.96 during trading hours on Thursday, reaching $744.45. 1,664,712 shares of the stock traded hands, compared to its average volume of 3,179,102. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The company has a market cap of $706.72 billion, a price-to-earnings ratio of 80.00, a PEG ratio of 2.76 and a beta of 0.43. The stock has a fifty day simple moving average of $872.25 and a 200 day simple moving average of $869.98. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion for the quarter, compared to analysts' expectations of $12.09 billion. During the same period in the previous year, the firm earned $0.10 EPS. The firm's quarterly revenue was up 20.4% compared to the same quarter last year. On average, equities analysts forecast that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company's payout ratio is presently 56.22%.

Wall Street Analyst Weigh In

LLY has been the topic of several analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. Citigroup increased their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a "buy" rating in a research note on Friday, October 25th. Bank of America reduced their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a "buy" rating on the stock in a report on Thursday, October 31st. BMO Capital Markets increased their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an "outperform" rating in a report on Friday, August 9th. Finally, Evercore ISI raised Eli Lilly and Company to a "hold" rating in a report on Thursday, September 5th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,007.94.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.